Table 4. Effect of Pyridine Substitution on CYP11B2 and B1 Inhibition and LLE.

compd	R1	R2	R3	R4	CYP11B2a (IC50, nM)	CYP11B1a (IC50, nM)	B1/B2b	LLEc
23	F	F	H	H	2.1	370	176	5.45
26	F	F	H	F	4.7	435	93	5.01
27	F	F	H	CN	22.3	1552	70	4.54
28	F	F	H	OCH3	0.4	250	606	6.12
29	F	Cl	H	F	0.8	251	296	5.20
30	F	CN	H	F	1.0	225	225	5.89
31	F	F	H	C(CH3)2OH	0.3	42	140	6.32
32	H	F	H	C(CH3)2OH	2.3	142	71	5.70
33	F	F	CH3	H	10.2	723	71	4.28
34	F	F	CF3	H	8.1	795	98	3.92
35	F	F	CH3	F	0.5	258	553	5.38
36	F	F	CH3	CH3	0.2	17.7	74	5.50
37	F	F	OCH3	CH3	0.6	435	709	5.52

^aAssay details reported in Supporting Information.

^bRatio of hCYP11B1 IC₅₀/hCYP11B2 IC₅₀.

^cLigand lipophilic efficiency; LLE = pIC₅₀ – a Log P₉₈.